Workflow
康辰药业(603590):营销转型和商誉计提影响短期业绩,创新研发成果显著
603590Konruns(603590) 平安证券·2025-04-28 10:49

Investment Rating - The report maintains a "Recommended" rating for the company [1][8][13] Core Views - The company's short-term performance is impacted by marketing transformation and goodwill impairment, but significant achievements in innovative research and development are noted [1][7][8] - The company reported a revenue of 825 million yuan for 2024, a year-on-year decrease of 10.28%, and a net profit of 42 million yuan, down 71.94% year-on-year [3][7] - The first quarter of 2025 shows a recovery trend with a revenue of 212 million yuan, up 6.41% year-on-year, and a net profit of 44 million yuan, up 6.83% year-on-year [3][7] Financial Performance Summary - Revenue and net profit projections for 2025 and 2026 are optimistic, with expected revenues of 990 million yuan and 1.131 billion yuan respectively, and net profits of 133 million yuan and 177 million yuan [6][11] - The company’s gross margin remains stable at around 89%, while net profit margin is expected to improve from 5.1% in 2024 to 16.7% by 2027 [6][11] - The report highlights a significant increase in R&D investment, which reached 139 million yuan in 2024, accounting for 16.83% of revenue [7][8] Market and Competitive Position - The marketing transformation from an alliance model to a digital empowerment model is expected to enhance sales efficiency and reduce sales expenses by 12.81% [7][8] - The company is optimistic about the potential recovery of its main business and the gradual realization of innovative successes, particularly with projects like KC1086 [8]